Efficacy and safety of National Centralized Drug Procurement-procured versus non-National Centralized Drug Procurement oxaliplatin in unresectable or metastatic pancreatic cancer: a retrospective cohort study
Authors:
Open Access
- 1 May 2026
- journal article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (5) , 391
Abstract
Background: China’s National Centralized Drug Procurement (NCDP) policy has substantially reduced the cost of essential medicines, yet concerns persist regarding the real-world therapeutic equivalence of NCDP-procured drugs compared to their non-NCDP counterparts. This study aimed to systematically evaluate, using real-world data, the comparative efficacy and safety of NCDP-procured versus non-NCDP oxaliplatin in patients with advanced pancreatic cancer. Methods: This single-center retrospective cohort study enrolled patients with unresectable or metastatic pancreatic cancer who received first-line mFOLFIRINOX between May 2022 and March 2025. Patients were stratified into NCDP and non-NCDP groups based on the procurement source of oxaliplatin. Primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Safety was assessed by the incidence of adverse drug reactions (ADRs). Results: Among 168 enrolled patients (NCDP, n=77; non-NCDP, n=91), no significant between-group differences were observed in ORR (9.1% vs. 13.2%, P=0.47), disease control rate (57.1% vs. 63.7%, P=0.43), or median PFS [6.5 vs. 6.0 months; adjusted hazard ratio (HR) =1.034, 95% confidence interval (CI): 0.691–1.547, P=0.87]. However, the NCDP group exhibited significantly lower incidences of elevated aspartate aminotransferase (AST) (28.6% vs. 45.1%, P=0.04) and grade ≥3 anemia (2.6% vs. 15.4%, P=0.007), which remained significant after multivariable adjustment. After propensity score matching, baseline characteristics were well-balanced between groups (all P>0.10), and the primary findings remained consistent. The unit price of NCDP oxaliplatin (¥ 76/vial) was 45% of the price of the non-NCDP agent (¥ 170/vial), representing substantial cost savings. Conclusions: NCDP-procured oxaliplatin demonstrated comparable efficacy to non-NCDP alternatives in advanced pancreatic cancer, with a more favorable safety profile for specific hepatic and hematologic toxicities. These real-world findings support the translation of the national procurement policy into clinical practice, offering significant cost savings without compromising patient outcomes.Keywords
This publication has 17 references indexed in Scilit:
- Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective studyFrontiers in Pharmacology, 2025
- Knowledge, attitudes, and practices of outpatients regarding National centralized drug procurement policy: a multicenter cross-sectional study in North ChinaScientific Reports, 2025
- The dual role of VEGF-A in a complex in vitro model of oxaliplatin-induced neurotoxicity: Pain-related and neuroprotective effectsNeurotherapeutics, 2025
- Challenges for switching central nervous system and psychiatric medication products: A review of the literatureJournal of Psychopharmacology, 2025
- Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 2024
- Local causes of essential medicines shortages from the perspective of supply chain professionals in Saudi ArabiaSaudi Pharmaceutical Journal, 2023
- Essential medicines for cardiovascular diseases in India: Rapid appraisal of policies and processes at the subnational levelThe National Medical Journal of India, 2023
- The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective studyWorld Journal of Surgical Oncology, 2023
- First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world populationFuture Oncology, 2022
- Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single InstitutionCurrent Oncology, 2020